## Differentiation of the Cs in lung cancer: Cancer vs. COVID

Urgent referrals for cancer in general and for lung cancer specifically have fallen during the COVID-19 pandemic that will likely lead to an increase in mortality and morbidity from lung cancer. The appendix reproduces a submission by the Clinical Expert Group for lung cancer and mesothelioma which includes recommendations about differentiation of symptoms from lung cancer from those due to COVID-19 and recommendations for easy access of patients with concerning symptoms for assessment by primary care.

Overlapping symptoms means that the message to patients about early diagnosis is negated by the messages necessary to control the COVID pandemic.

As well as attempting to clarify the distinction between lung cancer and COVID-19, there needs to be easy access for patients to have their symptoms assessed if they think they might have lung cancer. Current arrangements in primary care are unlikely to help patients present early and do not specifically address the issue of overlapping symptoms. NHS 111 are in the process of releasing a change to their algorithm which will direct those with either a negative COVID test or a persistent cough for >3 weeks to a clinician, in most cases a GP, for further consultation. It is expected that this will help to appropriately triage a significant symptom overlap between lung cancer and COVID-19 along with reference to the recommendations below.

The following is a suggested mitigation for the overlapping symptoms of cough, breathlessness and fatigue.

Α	В	С
Features more suggestive of lung cancer	Indeterminate Features	Features more suggestive of COVID-19 infection
Overlapping symptoms are unaccompanied by COVID-19	Cough, unclear onset and persistence	Acute onset of:
symptoms:	Breathlessness, unclear onset and	Dry cough
<ul> <li>Unexplained persistent cough</li> </ul>	persistence	<ul> <li>Breathlessness</li> </ul>
<ul> <li>Unexplained persistent breathlessness</li> </ul>	Unclear if any fever	Fever
<ul> <li>Fatigue of duration &gt;4 weeks</li> </ul>		<ul> <li>Myalgia</li> <li>Loss of smell</li> <li>Loss of taste</li> </ul>
Persistent or recurrent chest infection	Flu-like symptoms lasting longer than 3 weeks.	
May be accompanied by more specific red-flag symptoms	weeks.	Close contact with a confirmed/ highly
of lung cancer including:	Feeling of chest tightness	suspected case of COVID-19
<ul><li>haemoptysis,</li></ul>		
• chest pain	Difficulty in taking a deep breath	

<ul> <li>weight loss</li> <li>appetite loss</li> <li>And examination / other findings:         <ul> <li>finger clubbing</li> <li>supraclavicular lymphadenopathy or persistent cervical lymphadenopathy</li> <li>chest signs consistent with lung cancer</li> <li>thrombocytosis.</li> </ul> </li> <li>Also consider risk factors for lung cancer:         <ul> <li>smoking history</li> <li>Age</li> <li>Asbestos exposure</li> </ul> </li> </ul>	Fatigue with duration <4 weeks  Recurrent chest infections with possible features of COVID-19  No other clear red flag symptoms	Initial flu-like symptoms for 1-2 weeks with onset of respiratory symptoms from 7-10 days.
Action:	Action:	Action:  Manage patient according to the latest
Arrange an urgent nasal/oropharyngeal swab for SARS-CoV-2 PCR and if negative:	Arrange a nasal/oropharyngeal swab for SARS-CoV-2 PCR and if negative:	guidelines on the management of COVID- 19.
Refer for Chest X-ray or direct to lung cancer service for CT and triage on the National Optimal Lung Cancer Pathway	Ask patient to self-isolate for 14 days and then review symptoms; if persistent refer as for <b>A</b>	
If PCR positive, manage according to current COVID-19 guidelines and review after 2 weeks if hospital admission not required; consider 2 week wait referral in patient recovered from COVID-19 in whom lung cancer suspected	If PCR positive, manage according to current COVID-19 guidelines and review after 2 weeks if not admitted to hospital	
If symptoms require urgent attention, consider emergency admission	If symptoms require urgent attention, consider emergency admission	

Authors: Matthew Evison, Seamus Grundy, Simon Bailey, Richard Booton, Rajesh Shah, Neil Bayman, Fiona Blackhall, Colin Lindsay, Liz Toy, Matthew Hatton, Denis Talbot, Sanjay Popat, David Gilligan, Yvonne Summers, Douglas West, Andrew Wilcock, Richard Lee, David Baldwin and members of the Lung Cancer Clinical Expert Group.